Quick Answer
Akari Therapeutics Plc reported Cash And Cash Equivalents At Carrying Value of $2.60 million for the year ending 2024.
- Akari Therapeutics Plc showed a decrease of -32.4% in Cash And Cash Equivalents At Carrying Value from 2023 to 2024.
- This data is from Akari Therapeutics Plc's annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2004 to 2024 (22 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Historical annual values: Fiscal year 2024: $2.60 million | Fiscal year 2023: $3.85 million | Fiscal year 2022: $13.25 million | Fiscal year 2021: $9.36 million | Fiscal year 2020: $14.06 million | Fiscal year 2020: $12.32 million | Fiscal year 2020: $12.75 million | Fiscal year 2020: $7.82 million | Fiscal year 2019: $5.73 million | Fiscal year 2019: $6.27 million | Fiscal year 2019: $2.74 million | Fiscal year 2019: $6.15 million | Fiscal year 2018: $5.45 million | Fiscal year 2017: $28.11 million | Fiscal year 2016: $34.10 million | Fiscal year 2015: $68.92 million | Fiscal year 2014: $3.33 million | Fiscal year 2013: $553.7 thousand | Fiscal year 2012: $1.10 million | Fiscal year 2011: $6.0 thousand | Fiscal year 2010: $9.0 thousand | Fiscal year 2004: $0.00.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: